Skip to content
Kalpvruksh Markets
Offline Log in

QLINENSEOffline

Q-Line Biotech · INE1G2W01011
536.40+9.25 (+1.75%)last close · 05 Nov 2026
Prev close
527.15
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
—

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • MF schemes in Sept 2026: 1 bought, 0 cut · no promoter pledge
  • nothing scheduled or restricting

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.0×
median 41,800
Delivered
39,800
Of volume
82%

Price & trend

Price & trend

Not enough price historyFigures need 60 sessions of NSE prices.

Ownership

Who owns the company

% of all shares, by quarter

GroupSep 26
Promoters67.5%
FPI0.9%
Mutual funds2.2%
Other DII6.0%
Individuals18.4%
Others5.0%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Sep 26 none

Holders

Sep 26

All shareholders
2,948
Individuals
2,557

Which funds bought and sold

mutual funds · quarter ended

Funds holding
1
0 index · 1 active
Bought more
0
Sold some
0

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 2610100+4.1%₹35 cr
Aug 2610100+1.8%₹29 cr
Jul 2610100+22.9%₹26 cr
Jun 26100000.0%₹22 cr
May 2611000—₹19 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Q-Line Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.
    07 Sept 2026
  • Credit rating
    Q-Line Biotech Limited has informed the Exchange about Credit Rating- New
    24 Aug 2026
  • Board outcome
    Q-Line Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
    18 Jun 2026
  • Bulk deal: BUY
    1,50,000 at ₹452 — AFFLUENCE GEMS PRIVATELIMITED
    29 May 2026
  • Bulk deal: BUY
    1,50,000 at ₹452 — EXCELLENT SHARES AND FINANCE SERVICES PRIVATE LIMITED
    29 May 2026
  • Bulk deal: SELL
    400 at ₹451 — F3 ADVISORS PRIVATE LIMITED
    29 May 2026
  • Bulk deal: BUY
    1,23,600 at ₹454.03 — F3 ADVISORS PRIVATE LIMITED
    29 May 2026

Latest shown; 8 in six months on all disclosures.

QLINE: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.